Recordati stock gains after Barclays lifts its target

Published on 09/08/2026 at 23:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Recordati stock rises as Barclays lifts its target price to EUR 55 and the OPA on Recordati keeps interest high.

Moderne Pharma-Produktionsanlage mit Edelstahltanks und Glasfassade bei Tageslicht — Recordati S.p.A. (IT0003828271) betreibt moderne Pharma-Produktionsanlagen mit hochwertiger Fertigungstechnik am Firmensitz in Mailand, Italien, Illustration mit AI erstellt.

Recordati stock (IT0003828271) traded at EUR 51.90 on September 8, 2026, after a session that showed a 0.19 percent move from the prior day. The move came as Barclays raised its target price to EUR 55 from EUR 50 and kept an Equal Weight view, while the takeover offer for the Italian drugmaker stayed in the market's line of sight.

Barclays resets the target

Barclays lifted its Recordati target price to EUR 55 from EUR 50 on September 8, 2026, a 10 percent increase in the bank's valuation call. The same update left the recommendation at Equal Weight, which makes the new target the main change for investors rather than the stance itself.

Teleborsa reported on September 8, 2026, that the voluntary tender offer by Respighi BidCo had drawn 30,201 shares, equal to 0.015213 percent of the securities on offer, after 19,736 new tenders that day. The offer started on August 31, 2026, and is scheduled to end on October 15, 2026.

Chart stays near 52 euros

Borsa Italiana showed Recordati Ord at 51.90 on September 8, 2026, with the prior-day reference at 51.80 and a 0.19 percent change. MarketScreener placed the stock at EUR 52.00 in the same market snapshot, keeping the share price close to the 52-euro mark while Barclays' EUR 55 target leaves about EUR 3.10 of upside from the Borsa Italiana print.

The market cap line and volume were not needed to read the day's setup: price action stayed tight, and the 52 euro area became the immediate reference point for the stock.

Half-year numbers still matter

For the latest reported operating picture, Recordati's most recent figures remain the first half of 2026, with revenue at EUR 1,020.5 million and adjusted EBITDA at EUR 412.4 million, according to the company's interim reporting context. The group also said net income reached EUR 244.9 million, which gives the Barclays update a valuation backdrop that is still grounded in solid midyear profitability.

The comparison is clear: adjusted EBITDA of EUR 412.4 million in H1 2026 implies a margin of 40.4 percent on EUR 1,020.5 million of revenue, a level that helps explain why the stock can hold near EUR 52 even while the takeover process progresses.

Focus on the portfolio

Recordati's rare-disease and specialty portfolio remains the relevant operating anchor, because the H1 2026 profit base and the offer process both run through that business mix. The current price level near EUR 52 puts that portfolio value directly in play for both minority investors and bidders.

Price and venue

Recordati stock ended the latest quoted session at EUR 51.90, and the Barclays target of EUR 55 leaves the share a little above 6 percent below that level. The primary venue is Borsa Italiana in Milan, and the stock closed the day with the market still focused on the offer terms and the first-half earnings base.